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Abstract
Background:  The World Health Organization's (WHO) case definition for childhood pneumonia,
composed of simple clinical signs of cough, difficult breathing and fast breathing, is widely used in resource
poor settings to guide management of acute respiratory infections. The definition is also commonly used
as an entry criteria or endpoint in different intervention and disease burden studies.
Methods: A group of paediatricians conducted a retrospective review of clinical and laboratory data
including C-reactive protein concentration and chest radiograph findings among Filipino children
hospitalised in the Bohol Regional Hospital who were enrolled in a pneumococcal vaccine efficacy study
and had an episode of respiratory disease fulfilling the WHO case definition for clinical pneumonia. Our
aim was to evaluate which disease entities the WHO definition actually captures and what is the probable
aetiology of respiratory infections among these episodes diagnosed in this population.
Results: Among the 12,194 children enrolled to the vaccine study we recorded 1,195 disease episodes
leading to hospitalisation which fulfilled the WHO criteria for pneumonia. In total, 34% of these episodes
showed radiographic evidence of pneumonia and 11% were classified as definitive or probable bacterial
pneumonia. Over 95% of episodes of WHO-defined severe pneumonia (with chest indrawing) had an acute
lower respiratory infection as final diagnosis whereas 34% of those with non-severe clinical pneumonia had
gastroenteritis or other non-respiratory infection as main cause of hospitalisation.
Conclusion:  The WHO definition for severe pneumonia shows high specificity for acute lower
respiratory infection and provides a tool to compare the total burden of lower respiratory infections in
different settings.
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Background
The World Health Organization (WHO) has developed
standard case management guidelines to reduce the two
million deaths, or 20 percent of all child deaths, caused by
pneumonia through early diagnosis and treatment [1]. A
meta-analysis showed that these guidelines, if effectively
implemented, result in significant reduction in mortality:
24% (95% CI 14–33%) in total mortality and 36% (95%
CI 20–48%) in pneumonia-related mortality in children
aged 0 to 4 years in developing countries with infant mor-
tality over 90 per 1,000 live births [2]. Many countries
have now adapted these guidelines as part of national
acute respiratory infections control and Integrated Man-
agement of Childhood Illnesses (IMCI) programs.
The WHO guidelines define pneumonia as an acute dis-
ease episode with cough or difficult breathing combined
with fast breathing with age specific cut-off values for
increased respiratory rate. Children with lower chest wall
indrawing classified as severe pneumonia are referred for
evaluation and possible in-patient care. While it is esti-
mated that these criteria detect over 80 percent of children
that require antibiotic treatment for probable bacterial
pneumonia or hospital care for severe disease, 20 to 30
percent of children fulfilling the criteria receive unneces-
sary antimicrobials for non-severe viral respiratory infec-
tion [3]. This is especially true for children with expiratory
wheezing due to asthma, bronchiolitis or other viral respi-
ratory infections who are often misclassified as pneumo-
nia requiring antimicrobial treatment and referred for in-
patient care [4].
Another problem of the low specificity of the WHO defi-
nition for pneumonia is its use as study enrolment criteria
or one of the study endpoints in disease burden and inter-
vention studies. For example, studies evaluating the effi-
cacy of new conjugated vaccines against Streptococcus
pneumoniae show these vaccines are effective in reducing
invasive pneumococcal disease and radiographic pneu-
monia, but the efficacy is low for the WHO-defined clini-
cal pneumonia [5,6].
We carried out a randomised, double-blinded, placebo-
controlled study to evaluate the efficacy of an investiga-
tional 11-valent pneumococcal conjugate vaccine against
childhood pneumonia in the Philippines. We used the
WHO definition for pneumonia as entry criteria for clini-
cal data collection from study subjects hospitalised and as
a secondary endpoint for vaccine efficacy analysis. This
report describes, without un-blinding the study randomi-
sation code, results of a retrospective review of clinical,
laboratory and radiological data from study subjects hos-
pitalised with an illness that on admission fulfilled the
WHO definition for pneumonia. Our aim was to describe
the clinical methods used in our vaccine study and evalu-
ate the use of WHO definition for clinical pneumonia in
a South East Asian paediatric hospital setting. We
attempted to improve the specificity of diagnosis of WHO
defined clinical pneumonia by classifying the disease epi-
sodes into International Classification of Diseases, ver-
sion 10 (ICD-10)-classification system categories for
pneumonia which then could be used to analyse the vac-
cine efficacy. The results are discussed in light of possible
different diagnostic approaches for respiratory infections,
which could be utilised in pneumococcal or other vaccine
and disease burden studies.
Methods
Study setting
The study was conducted in six municipalities in Bohol
Province in central Philippines. At the beginning of the
vaccine study in 2000, the predominantly agricultural
area covering 357 Km2 had a total population of 149,000.
There is no malaria and practically no HIV in Bohol [7]. In
2005, the Gross National Income of the Philippines was
1,300 USD/capita. The infant mortality rate (IMR) in
Bohol during years 1999–2002 was 28/1,000 live births,
with the major causes of child deaths being pneumonia
and diarrhoea [7].
Study subjects
This study to evaluate the efficacy of an 11-valent mixed
carrier tetanus protein or diphtheria toxoid conjugated
pneumococcal vaccine against radiographic pneumonia
in children aged 6 weeks to 23 months started in July
2000. All children born in the study area and healthy
enough to receive their first diphtheria, tetanus, whole-
cell pertussis vaccine (DTwP) dose according to the
national Expanded Program on Immunization (EPI) pro-
gram were offered study participation. The vaccines
administered included Bacillus-Calmette-Guerin (BCG)
at 2 weeks of age, 3 doses of DTwP and Haemophilus influ-
enzae type b (DTwP//PRP-T) conjugate vaccine, plasma
derived hepatitis B vaccine and study vaccine or placebo
(normal saline) starting at age of 6 weeks to < 6 months
with a minimum interval of 4 weeks between the doses.
Measles vaccine was given at 9 months of age.
Case ascertainment for pneumonia
Patients described in this paper were evaluated at the
Bohol Regional Hospital, which is a 250-bed tertiary gov-
ernment hospital managing approximately 85% of chil-
dren with severe infections aged less than 5 years from the
study area [8]. Most of the children were walk-in patients
without referral from the primary health care clinics. All
children were seen within 30 minutes of arrival by a study
nurse who screened whether the patient's age (6 weeks to
23 months), residency (six study municipalities) and
symptoms met the criteria for data collection. The eligibil-
ity was then immediately reconfirmed by a physician. ABMC Infectious Diseases 2008, 8:95 http://www.biomedcentral.com/1471-2334/8/95
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community acquired pneumonia was defined as pneumo-
nia with onset prior to or less than 72 hours following
admission to hospital. The WHO criteria for non-severe
pneumonia included: a history of cough and/or difficult
breathing of less than 3 weeks duration, with (a) increased
respiratory rate (Rate ≥ 60/min if age <2 months, ≥ 50/
min if age 2–11 months and ≥ 40/min if age 12–59
months); (b) lower chest wall indrawing (severe pneumo-
nia); or (c) cyanosis and/or inability to feed or drink (very
severe pneumonia). In case of expiratory wheezing on
auscultation the child was first given three doses of an
inhaled bronchodilator, and the eligibility was re-assessed
30 minutes after the last dose. The child was further eval-
uated according to the study procedures if the signs and
symptoms of WHO-defined pneumonia were still present
after the bronchodilator treatment. New admission due to
a disease meeting the WHO pneumonia criteria within 14
days of the previous evaluation was considered to belong
to the same disease episode. The haemoglobin oxygen sat-
uration at room air was measured with BCI 3303 oximeter
(Waukesha, USA) after stabilization of the reading. A
blood sample was drawn for bacterial culture, white
blood cell count (Advia 60 automatic analyzer, Bayer,
USA), and serum. The bacterial cultures were conducted
by using standard methods [Methods described in detail
in references [9] and [10]]. Regular quality control of bac-
terial culture techniques and findings were conducted by
the Research Institute for Tropical Medicine in the Philip-
pines and National Public Health Institute in Finland.
Coagulase negative staphylococci, Bacillus, diphtheroids
and gram negative non-fermenting organisms were con-
sidered contaminants. The serum samples were trans-
ported frozen to Finland for analysis of C-reactive protein
by immunoturbidometry and radioimmunoassay
(Hitachi Modular P1-analyser, Hitachi Ltd, Tokyo, Japan)
at the Helsinki University Central Hospital. All patients
were subjected to chest radiograph which was interpreted
by using a reading process developed by the WHO [11].
The radiographs were also interpreted separately using a
structured questionnaire by an independent pediatric
radiologist blinded to the clinical data. Survival of all
study subjects was checked by the study team at the age of
23 months, or following the termination of the study data
collection in December 2004.
Quality assurance of case ascertainment
The study nurses and physicians were trained in the WHO
pneumonia-management algorithm [12,13] and were
monitored weekly for accuracy and consistency of meas-
urement of respiratory rate, chest indrawing and other
signs of pneumonia. The intensive monitoring kept the
inter-observer variation in pneumonia severity assessment
at less than 10% during the study period. All data were
double entered into the study database. An independent
monitoring team consisting of clinical research associates
constantly checked the integrity of all clinical study data.
Review of patient data by the clinical review team
The retrospective review of clinical data collected during
2000 to 2004 from each disease episode was carried out
from November 2003 to March 2005 by a team consisting
paediatricians familiar with the study setting (TP, BQ, EA-
L, SL, TH-K). Structured data from the study database (as
shown in Table 1) and non-structured admission and
daily follow-up data from the hospital records, as well as
results of laboratory and radiology investigations were
used as source data. The review team utilised the Interna-
tional Classification of Diseases, version 10 (ICD-10) cod-
ing system to record final diagnoses for each disease
episode. Disease episodes with clinical signs and symp-
toms of infection and infiltrates or pleural fluid in chest
radiograph were classified as pneumonia whereas those
episodes with normal or missing chest radiograph as clin-
ical lower respiratory tract infection. The review team also
further classified the pneumonia episodes according to
the probable aetiology, i.e. to bacterial, mixed bacterial-
viral and viral infections, by using the best clinical judge-
ment based on clinical data, C-reactive protein concentra-
tion, white blood cell count, radiographic appearance and
response to treatment with or without antimicrobials.
Underlying medical conditions such as malnutrition and
congenital abnormalities were also registered. The most
important medical condition leading to hospitalisation
was regarded as the primary diagnosis. The intra-observer
variability of the review process was evaluated in approx-
imately 10 percent of episodes by repeating the review
several months later blinded to the results of the first
review.
Ethical review and approvals
The parents or guardians of study subjects signed an
informed consent before enrolment to the vaccine study.
All therapeutic decisions were done independently by reg-
ular hospital physicians not belonging to the study team.
The study was conducted in accordance with the latest
South African revision of the Declaration of Helsinki, ICH
Good Clinical Practice, and local regulatory requirements.
The concept of the trial submitted under title "Phase III
Trial on the Efficacy of an 11-Valent Pneumococcal Con-
jugate Vaccine in the Reduction of Severe and Very Severe
Pneumonia Among Filipino children Under 2 Years of
Age" was approved by the Ethical and Institutional Review
Board of the Research Institute of Tropical Medicine, the
Philippines in November 1998. The final version of the
trial protocol was approved in June 2000.BMC Infectious Diseases 2008, 8:95 http://www.biomedcentral.com/1471-2334/8/95
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Statistical analysis
This report describes the clinical picture of pneumonia
requiring hospitalisation and the method of clinical
review used in our vaccine efficacy study context. No sta-
tistical hypothesis testing was conducted. We calculated
Kappa coefficient for the reproducibility of the review.
Results
The planned cohort of 12,194 infants was enrolled the
vaccine efficacy study by December 2003 (78% of the
total birth cohort, 92% of the non-transient population
eligible for the study). Overall, 98.7% of the enrolled sub-
jects received 3 doses of study vaccine. The median age at
vaccination was 1.8, 2.9 and 3.9 months for first, second
and third dose, respectively. Vaccine and placebo groups
did not differ in key baseline socio-economic indicators
(data not shown). The data on all hospital admissions
and other important medical events were collected until
study termination visit at 23 months of age (N = 8,780) or
end of study follow up at the end of December 2004 (N =
2,366). Altogether 64 children died and 984 children were
lost to follow up due to migration or were withdrawn
from the study for various reasons.
This analysis covers 1,195 disease episodes fulfilling the
WHO criteria for pneumonia among 821 children (60%
boys) who were hospitalised at the Bohol Regional Hos-
pital. The age distribution is shown in Table 1 [see Addi-
tional file 1]. According to the WHO pneumonia severity
classification algorithm, 290 episodes (24%) were non-
severe pneumonia i.e. without chest indrawing or other
danger signs, 785 (66%) were severe pneumonia present-
ing with chest indrawing and 120 (10%) were very severe
pneumonia with either inability to drink or central cyano-
sis. A blood culture was obtained in 90% of episodes. We
detected 13 (1.1% of episodes) invasive bacterial infec-
tions. The most common bacterial pathogens included
Staphylococcus aureus, Streptococcus pneumoniae and Salmo-
nella  Typhi. Chest radiographs from 182 (15.2%) epi-
sodes showed abnormal findings which met the WHO
criteria for probable bacterial pneumonia (Primary end-
point consolidation). The mean duration of hospitalisa-
tion was 3.2 days (Range 0 to 32 days). Altogether 19
patients died while in hospital or within 14 days from dis-
charge (Case fatality rate 1.6%).
The distribution of key clinical, laboratory and radiology
findings in each of the WHO pneumonia severity catego-
ries is shown in Table 1 [see Additional file 1]. In episodes
of severe, but not very severe pneumonia, 51% of children
presented with expiratory wheeze compared to 9.3% in
the non-severe and 40.8% in the very severe pneumonia
categories. Very severe pneumonia was associated with
highest probability for abnormal radiograph and hypox-
emia, as well as the highest case fatality rate: 9.2% com-
pared to 0.3% in non-severe pneumonia and 0.5% in
severe pneumonia categories.
The WHO classifications of severe and very severe pneu-
monia identified acute lower respiratory infection very
well (95% and 85% respectively) whereas the non-severe
pneumonia classification identified only 49% of subjects
with ALRI. According to the retrospective review of clini-
cal, laboratory and radiographic data, 402 episodes
(33.6%) had radiographically confirmed pneumonia as
the major cause of hospitalisation (Table 2) [see Addi-
tional file 1]. Bacteriologically confirmed bacterial pneu-
monia or probable bacterial pneumonia was the
diagnosis in 8.6%, 11.5% and 15.9% of episodes in non-
severe, severe and very severe WHO pneumonia catego-
ries, respectively. Viral lower respiratory infection i.e. viral
pneumonia or bronchiolitis was most common in the
severe pneumonia category: 37.5% compared to 14.5%
and 25.9% in non-severe and very severe pneumonia cat-
egories, respectively.
A total of 203 episodes (17.0%) were evaluated as not
having a lower respiratory infection as the main reason for
hospitalisation. Non-respiratory diseases, of which acute
gastroenteritis was the most common, accounted for
12.7% of hospitalisations. The other non-respiratory diag-
noses included a broad range of paediatric diseases such
as acute febrile infections with seizures, skin infections,
urinary tract infections and 9 cases of central nervous sys-
tem infections.
Episodes which fulfilled the WHO criteria for non-severe
pneumonia had the highest likelihood for having a non-
respiratory disease as the main diagnosis. However, in 15
of the 37 episodes of acute gasteroenteritis the child had
also signs of lower respiratory infection (3 with radio-
graphic abnormalities). In total, seven of the 290 (2.4%)
of episodes were diagnosed as sepsis or meningitis. In the
severe pneumonia group, other than lower respiratory
infection diagnoses were rare. The 12 episodes of gaste-
roenteritis included one episode, in which the patient also
had a diagnosis of viral pneumonia. The 11 other epi-
sodes presented with chest indrawing on admission, but
this could have been due to dehydration or simultaneous
lower respiratory infection which did not show any radio-
graphic abnormalities. Only in two episodes, the final
diagnosis was meningitis or sepsis without pneumonia.
The other diagnoses in the very severe pneumonia group
included five episodes of sepsis, four episodes of central
nervous system infections and three episodes of acute gas-
troenteritis. One episode was classified as an upper respi-
ratory infection.
In order to ensure the reproducibility of the review, 111
episodes (9.3%) were re-evaluated several months later byBMC Infectious Diseases 2008, 8:95 http://www.biomedcentral.com/1471-2334/8/95
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the same review team who were blinded to the results of
the first review round. The team assigned the same ICD-
10 coded diagnosis in 79 of the 111 episodes evaluated
(71.2%). Additional 21 episodes (18%) had diagnosis in
the same disease group, but the ICD-10 coding differed
(e.g. J22 non-specified lower respiratory infection vs.
J21.9 bronchiolitis). A total of 37 episodes were assigned
a pneumonia group diagnosis in the first review com-
pared to 44 in the second review (Kappa coefficient 0.79).
According to both reviews 93 episodes had a diagnosis
belonging to any of lower respiratory tract infection cate-
gories (Kappa 0.87).
Discussion
Our study demonstrates that in this population of Fili-
pino children the WHO definition of clinical pneumonia
captures a broad spectrum of respiratory infections vary-
ing from mild upper respiratory infections to severe bacte-
rial pneumonia. In total, one third of episodes showed
radiographic evidence of pneumonia and one third of
these (11.2% of the total) were classified by the group of
paediatricians as definitive or probable bacterial pneumo-
nia. The severity of the disease correlated well with the
WHO pneumonia severity algorithm. The non-severe
pneumonia group had a higher probability for upper res-
piratory and non-respiratory group diagnoses than the
severe or very severe pneumonia groups which identified
very well the lower respiratory and other severe infections.
The findings of this study are in conformity with other
studies conducted in the Philippines [14,15] and in other
Asian countries [4] reporting a similar clinical picture in
patients with a WHO-defined pneumonia. The case fatal-
ity rate of 0.5% observed in the severe pneumonia group
was similar to that in a recent multi-centre study evaluat-
ing antimicrobial treatment alternatives for WHO-defined
severe pneumonia [16], but lower than the 2.1% and 12%
mortality described in Bohol, the Philippines during
1990's and in Lombok, Indonesia among children hospi-
talised for acute lower respiratory infection, respectively
[17,18]. This may reflect the different patterns in care
seeking behaviour and access to care.
The microbial aetiology of respiratory infection is difficult
to determine, as the sensitivity of tests, especially bacterial
cultures, is low, and mixed bacterial and viral infections
are common. The chest radiograph and non-specific labo-
ratory markers such as C-reactive protein, procalcitonin
and white blood cell count provide some guidance, but
the results overlap significantly in viral and bacterial
pneumonia [19,20]. In this study the WHO classification
of non-severe, severe and very severe pneumonia
appeared to correlate with disease severity, but poorly
with the probability of definitive or probable bacterial
aetiology for infection. The distributions of C-reactive
protein concentration and blood leukocyte count did not
suggest major differences in proportions of episodes with
bacterial aetiology in the different severity categories of
pneumonia. Despite special attention to laboratory tech-
niques the ratio of positive blood culture findings was low
in all pneumonia severity categories. This may be partly
explained by Hib vaccination provided to all study partic-
ipants and pre-hospital antimicrobial treatment, which
was, according to a parental questionnaire, 35% in our
previous epidemiologic study conducted in Bohol during
1995–99 [9]. Nevertheless the overall ratio of invasive
pneumococcal infections is far lower than those seen in
studies in Africa [21]. In this study 15.2% of episodes
showed a primary endpoint consolidation in chest radio-
graph. The frequency of chest radiograph findings
increased with the pneumonia severity. The Gambian
pneumococcal study, which used similar WHO criteria for
case ascertainment, reported a primary endpoint radio-
graphic finding in 18.1% of hospitalized children [5].
However, in the Gambian study, 4.2% of hospitalized
patients had a blood culture or CSF positive for Streptococ-
cus pneumonia compared to 0.3% in this study population.
Other studies have reported 65% to 90% specificity of the
WHO pneumonia criteria for lower respiratory infection
[3,12,13,21]. In our study, the retrospective clinical review
demonstrated that in 17% of episodes the child showed
signs and symptoms of WHO-defined pneumonia, but
the main condition prompting the decision to admit the
patient for hospital care was not the acute lower respira-
tory infection. Largely this consists of patients with non-
severe pneumonia, of which over half had another con-
comitant disease that was the main reason for hospitalisa-
tion. According to the WHO guidelines the children with
non-severe pneumonia should not be referred for hospital
care, but provided with oral antibiotics for acute respira-
tory infection. Among children with severe pneumonia
presenting with chest indrawing, the frequency of con-
comitant disease prompting the decision for admission
was low (< 5%). The episodes of very severe pneumonia
included, in addition to lower respiratory infections, also
other severe infections. This finding supports the current
practise of including these patients to the IMCI guidelines
category of severe disease needing urgent referral to hospi-
tal care.
We noted expiratory wheeze in half of episodes of WHO
defined severe pneumonia. This finding emphasises the
importance of including the management of wheeze to
the current pneumonia management guidelines. It is not
known whether all children with wheeze, presumable
caused by a viral infection, require antimicrobial therapy
and, if not, which additional clinical findings would sup-
port withholding antibiotics [3,4]. The WHO currently
recommends that children without previous history ofBMC Infectious Diseases 2008, 8:95 http://www.biomedcentral.com/1471-2334/8/95
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wheeze who develop a lower respiratory infection with
wheeze and tachypnoea may have a bacterial or mixed
bacterial-viral infection, and should always be treated
with antibiotics for suspected bacterial pneumonia [23].
The findings from the South African pneumococcal study,
which reported 31% efficacy of the vaccine against pneu-
monia associated to respiratory viruses support this strat-
egy [24]. The situation may, however, be different in
many Asian countries where the incidences of wheezing
diseases and paediatric asthma have increased and mor-
tality attributable to severe respiratory infections has
decreased [3,25,26].
A limitation of this study is the uncertainty of the role of
the pneumococcal conjugate vaccine in modifying the
clinical picture of respiratory infections. Other pneumo-
coccal vaccine efficacy studies suggest that the vaccine may
prevent 20–36% of radiographic pneumonia [5,6]. It is
thus possible that viral respiratory infections are enriched
in this patient population. We assumed that in 5% of epi-
sodes where a chest radiograph was not obtained the clin-
ical review diagnosis was not pneumonia. While probably
missed some infiltrates we do not believe that the overall
interpretation of the data would have changed signifi-
cantly. The diagnostic procedures conducted in this study
represent practices available in many hospitals in South
East Asian countries. The results of this study are not,
however, directly applicable to other health care settings,
in which the clinical picture of WHO-defined clinical
pneumonia may be different. The reproducibility of our
clinical case review process was high in our own study set-
tings, but it is difficult to know if this process, based pri-
marily on clinicians' best judgement, could be repeated in
similar manner elsewhere. Whether the classification
according to probable aetiology of infection was success-
ful can be evaluated once we analyse the vaccine efficacy
in different ICD-10 categories of respiratory infections
and complete the on-going testing of respiratory viruses
from nasopharyngeal samples collected from hospitalized
study children.
The WHO case management algorithm for pneumonia
provides an important tool for managing respiratory
infection in resource poor settings. It also provides a tool
to compare the total burden of respiratory infections in
different communities, but should not, without addi-
tional microbiological evidence, be used to compare the
burden attributable to specific respiratory pathogens. This
study suggests that the category of WHO-defined severe
pneumonia is very specific for lower respiratory infections
whereas the non-severe pneumonia category includes, at
least in hospital settings, a large proportion of other dis-
eases.
Conclusion
The WHO definition for clinical pneumonia captures a
broad spectrum of different paediatric respiratory dis-
eases. The WHO classification of non-severe, severe and
very severe pneumonia correlated well with disease sever-
ity, but poorly with the probability of definitive or proba-
ble bacterial aetiology for infection. The category of severe
pneumonia presenting with chest indrawing showed high
specificity for lower respiratory infection, and could be
used when comparing the burden of respiratory infections
in resource poor countries.
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